In the latest clinical trial of the Hdm2 Inhibitor in R/R AML for an overall survival (MIRROS) clinical trial, idasanutlin (RG7388) was combined with cytarabine with or without allogeneic hematopoietic stem cell transplant (HSCT) in patients with refractory or relapsed acute myeloid leukemia (R/R AML) [33,34]. The gene discussed is MDM2; the disease is acute myeloid leukemia.